Plato Investment Management Ltd Purchases New Shares in Bioventus Inc. (NYSE:BVS)

Plato Investment Management Ltd purchased a new stake in shares of Bioventus Inc. (NYSE:BVS) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,620 shares of the company’s stock, valued at approximately $38,000.

Other hedge funds also recently made changes to their positions in the company. Virtus Fund Advisers LLC bought a new stake in Bioventus in the third quarter worth $42,000. Quest Partners LLC bought a new stake in Bioventus in the third quarter worth $51,000. Quarry LP bought a new stake in Bioventus in the third quarter worth $59,000. Covestor Ltd bought a new stake in Bioventus in the third quarter worth $69,000. Finally, EP Wealth Advisors LLC bought a new stake in Bioventus in the third quarter worth $144,000. 62.94% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on BVS. Canaccord Genuity Group boosted their target price on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and boosted their target price for the stock from $12.00 to $13.00 in a report on Tuesday, December 17th.

Bioventus Stock Up 1.0 %

BVS stock opened at $10.19 on Thursday. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38. The business has a fifty day moving average price of $10.22 and a 200-day moving average price of $10.99. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock has a market capitalization of $826.97 million, a P/E ratio of -16.70 and a beta of 0.85.

Insider Transactions at Bioventus

In related news, CFO Mark Leonard Singleton sold 6,498 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the sale, the chief financial officer now owns 118,817 shares in the company, valued at approximately $1,210,745.23. This represents a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Katrina J. Church sold 2,535 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total value of $26,693.55. Following the sale, the senior vice president now owns 47,264 shares of the company’s stock, valued at approximately $497,689.92. This trade represents a 5.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 52,932 shares of company stock worth $512,511 over the last quarter. 32.90% of the stock is currently owned by insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.